Evil Mass-Murdering Pfizer to Test 3rd ‘Covid’ Shot in Kids Under 5 After Two Doses Fall Short

December 21, 2021 covid19

Pfizer and BioNTech will expand their clinical trial to include a third dose of their COVID vaccine on infants and children 6 months to 5 years old after the company said two doses failed to trigger a sufficient immune response in 2- to 5-year-olds.

Pfizer and BioNTech will test a third dose of their COVID vaccine on infants and children 6 months to 5 years old after the company said two doses failed to trigger a sufficient immune response in 2- to 5-year-olds.

The companies said on Dec. 17 they amended their clinical trial to include a third shot for the age group at least two months after the initial two-dose regimen.

The companies tested a 3 microgram dose of the vaccine — one-tenth of the adult dose — in children 6 months to 5 years of age. After two doses, children between 6 months and 2 years produced an immune response comparable to people aged 16 to 25 years, but children between 2 and 5 years old did not.

“The study will now include evaluating a third dose of 3 [micrograms] at least two months after the second dose of the two-dose series to provide high levels of protection in this young age group,” the companies said in a press release.

In a Dec. 17 conference call with investors and analysts, Kathrin Jansen, Pfizer’s head of vaccine research, said if the revised strategy works, “we would have a consistent three-dose vaccine approach for all ages.”